PAR MDUK 032.

Methods	Six‐week, randomised, double‐blind, double‐dummy, parallel‐group comparative study.
Participants	Male and female patients, aged 18 to 75 years, suffering from reactive or endogenous unipolar depression according to the DSM‐III criteria, considered suitable for treatment with anti‐depressant drugs, and also having a minimum score of 17 on the first 17 items of the Hamilton rating scale for depression (HDRS‐21), were eligible for the inclusion in the study.
Interventions	Paroxetine: 29 participants. Amitriptyline: 30 participants. Paroxetine dose range: 20‐30 mg/day. Amitriptyline dose range: 100‐150 mg/day.
Outcomes	HDRS‐21, Physician's Global Assessment of Severity of Illness (PGAS). Total dropout, dropout due to side‐effects, dropout due to inefficacy. Number of patients experiencing at least one side effect, side‐effect profile.
Notes	Funding: paroxetine manufacturer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "the main analyses were carried out on the Inten‐to‐treat (ITT) population using the extender dataset ‐ a dataset that has missing values imputed by Last Observation Carried Forward (LOCF)".
Selective reporting (reporting bias)	High risk	Continuous outcomes data reported without Standard deviations.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.